NASDAQ:CDTX - Cidara Therapeutics Stock Price, Forecast & News

Cidara Therapeutics trades on the NASDAQ under the ticker symbol "CDTX."

Cidara Therapeutics Inc (NASDAQ:CDTX) posted its earnings results on Thursday, November, 7th. The biotechnology company reported $0.08 earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.34. The biotechnology company earned $19.10 million during the quarter, compared to analyst estimates of $30 million. View Cidara Therapeutics' Earnings History.

Cidara Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Cidara Therapeutics.

6 brokerages have issued 1-year price objectives for Cidara Therapeutics' shares. Their forecasts range from $4.00 to $10.00. On average, they expect Cidara Therapeutics' share price to reach $6.88 in the next twelve months. This suggests a possible upside of 117.6% from the stock's current price. View Analyst Price Targets for Cidara Therapeutics.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cidara Therapeutics in the last year. There are currently 1 sell rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cidara Therapeutics.

Media headlines about CDTX stock have trended very negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cidara Therapeutics earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Cidara Therapeutics.

Cidara Therapeutics saw a drop in short interest during the month of January. As of January 31st, there was short interest totalling 1,230,000 shares, a drop of 7.5% from the January 15th total of 1,330,000 shares. Based on an average daily volume of 303,900 shares, the short-interest ratio is currently 4.0 days. Approximately 6.0% of the company's stock are short sold. View Cidara Therapeutics' Current Options Chain.

Some companies that are related to Cidara Therapeutics include Adaptimmune Therapeutics (ADAP), Precision BioSciences (DTIL), PDL BioPharma (PDLI), Cabaletta Bio (CABA), BioCryst Pharmaceuticals (BCRX), Harpoon Therapeutics (HARP), Gritstone Oncology (GRTS), Tcr2 Therapeutics (TCRR), Cellular Biomedicine Group (CBMG), Eiger Biopharmaceuticals (EIGR), Sutro Biopharma (STRO), Novavax (NVAX), ADMA Biologics (ADMA), La Jolla Pharmaceutical (LJPC) and CASI Pharmaceuticals (CASI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cidara Therapeutics investors own include Corbus Pharmaceuticals (CRBP), Anavex Life Sciences (AVXL), Sorrento Therapeutics (SRNE), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Agile Therapeutics (AGRX) and Viking Therapeutics (VKTX).

(CDTX) raised $60 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers.

Cidara Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include 5AM Venture Management LLC (6.07%), Renaissance Technologies LLC (2.41%), Bank of Montreal Can (0.54%), Oxford Asset Management LLP (0.52%), Jacobs Levy Equity Management Inc. (0.44%) and Raymond James Financial Services Advisors Inc. (0.38%). Company insiders that own Cidara Therapeutics stock include James E Levine, Jeffrey Stein, Jessica Oien, Neil Abdollahian and Paul Daruwala. View Institutional Ownership Trends for Cidara Therapeutics.

CDTX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc.. Company insiders that have sold Cidara Therapeutics company stock in the last year include Jessica Oien, Neil Abdollahian and Paul Daruwala. View Insider Buying and Selling for Cidara Therapeutics.

CDTX stock was bought by a variety of institutional investors in the last quarter, including 5AM Venture Management LLC, Bank of Montreal Can, Oxford Asset Management LLP, Jacobs Levy Equity Management Inc., Renaissance Technologies LLC, Acadian Asset Management LLC, Banco Bilbao Vizcaya Argentaria S.A. and Marshall Wace LLP. Company insiders that have bought Cidara Therapeutics stock in the last two years include James E Levine and Jeffrey Stein. View Insider Buying and Selling for Cidara Therapeutics.

Shares of CDTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CDTX stock can currently be purchased for approximately $3.16.

Cidara Therapeutics has a market capitalization of $104.41 million. The biotechnology company earns $-59,020,000.00 in net income (profit) each year or ($2.32) on an earnings per share basis. Cidara Therapeutics employs 68 workers across the globe.View Additional Information About Cidara Therapeutics.

The official website for Cidara Therapeutics is http://www.cidara.com/.

Cidara Therapeutics' mailing address is 6310 NANCY RIDGE DRIVE SUITE 101, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-752-6170 or via email at [email protected]